ESPR FY 2018 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

FY 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$184M

Gross Profit

$184M99.9% margin

Operating Income

-$205M-110.9% margin

Net Income

-$202M-109.4% margin

EPS (Diluted)

$-7.54

Cash Flow

Operating Cash Flow

-$149M

Free Cash Flow

-$149M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$143M

Total Liabilities

$64M

Stockholders' Equity

-$598M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$184M	$0	—
Gross Profit	$184M	-$258,000	+71498.8%
Operating Income	-$205M	-$169M	-21.1%
Net Income	-$202M	-$167M	-20.9%